去势抵抗性前列腺癌的研究及治疗进展  

Research Progress and Advances Therapy for Castration-resistant Prostate Cancer

作　　者：刘博[1] 张庆皎[1] LIU Bo;ZHANG Qing-jiao(Department of Urology,Tianjin Fourth Central Hospital,Tianjin,300140,China)

机构地区：[1]天津市第四中心医院泌尿外科,天津300140

出　　处：《黑龙江医学》2022年第1期125-128,共4页Heilongjiang Medical Journal

摘　　要：近年来前列腺癌发病率在我国呈上升趋势。雄激素剥夺治疗18-36个月后绝大多数患者会进展为去势抵抗性前列腺癌。随着对去势抵抗性前列腺癌的形成机制的研究以及治疗新药物的不断出现,延长了去势抵抗性前列腺癌患者的生存期,改善了生活质量。现对相关研究及治疗进展进行综述。In recent years,the incidence of prostate cancer has been on the rise in China.After 18-36 months of androgen deprivation treatment,most patients will progress to castration-resistant prostate cancer.In recent years,with the research on the formation mechanism of castration-resistant prostate cancer and the continuous emergence of new treatment drugs,the survival period of patients with castration-resistant prostate cancer has been prolonged and the quality of life has been improved.The article reviews related research and treatment progress.

关 键 词：去势抵抗性前列腺癌 机制 治疗 

分 类 号：R737.25[医药卫生—肿瘤]